← All indications
Hepatorenal Syndrome
Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.
Drugs by status
Approved for this indication (1)
Phase 4 trials (2)
Phase 3 trials (3)
Phase 2 trials (4)
Phase 1 trials (1)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (12)
- Novartis
- Mallinckrodt
- Orphan Therapeutics
- National Hepatology & Tropical Medicine Research Institute
- University of Pennsylvania
- University of Arizona
- Postgraduate Institute of Medical Education and Research
- University of Padova
- University of Alberta
- Virginia Commonwealth University
- University of Turin
- San Giovanni Battista Hospital, Turin
Organization Involved with Phase 2 Indications (3)
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (2)